Peroneal Electric Transcutaneous NeuroModulation (eTNM ® ): A Novel Method for the Treatment of the Overactive Bladder.

Autor: Krhut J; Department of Urology, University Hospital, Ostrava, Czech Republic.; Department of Surgical Studies Medical Faculty, Ostrava University, Ostrava, Czech Republic., Peter L; STIMVIA™, Ostrava, Czech Republic.; Department of Chemistry Faculty of Science, University of Hradec Králové, Hradec Králové, Czech Republic., Rejchrt M; Department of Urology, 2nd Faculty of Medicine of Charles University and Motol University Hospital, Prague, Czech Republic., Slovak M; STIMVIA™, Ostrava, Czech Republic., Skugarevska B; Department of Urology, University Hospital, Ostrava, Czech Republic.; Department of Surgical Studies Medical Faculty, Ostrava University, Ostrava, Czech Republic., Zvara P; Biomedical Laboratory and Research Unit of Urology Department of Clinical Research, University of Southern Denmark, Odense, Denmark.; Department of Urology, Odense University Hospital, Odense, Denmark.
Jazyk: angličtina
Zdroj: Journal of healthcare engineering [J Healthc Eng] 2021 Oct 06; Vol. 2021, pp. 4016346. Date of Electronic Publication: 2021 Oct 06 (Print Publication: 2021).
DOI: 10.1155/2021/4016346
Abstrakt: Overactive bladder syndrome (OAB) is a prevalent medical problem with a significant impact on the quality of life of the affected individuals. Pharmacotherapy is considered the main treatment method, although it is discontinued in a significant proportion of patients due to inefficacy or associated side effects. If pharmacotherapy fails, patients can undergo peripheral neuromodulation of the somatic nerves of the lower limb or sacral neuromodulation; however, neither of these represents an ideal therapeutic tool. The Peroneal electric Transcutaneous NeuroModulation (Peroneal eTNM ® ), based on the selective stimulation of the peroneal nerve, is the new fully noninvasive neuromodulation method intended to treat OAB. The URIS ® neuromodulation system, engineered to provide Peroneal eTNM ® , consists of the URIS ® device, URIS ® active electrodes, and the biofeedback foot sensor (BFS). The unique design of the URIS ® device and URIS ® active electrodes allows for the use of a low voltage and current during neuromodulation, which significantly reduces the unpleasant sensations. The BFS allows for precise localization of the active electrodes and for continuous adjustment of the voltage and frequency to achieve the optimal therapeutic effect. The URIS ® system adopts several principles of telemedicine, which makes it compatible with the US Food and Drug Administration (FDA) and European Union (EU) regulations for home-based use. This article describes both the Peroneal eTNM ® method and the URIS ® neuromodulation system, including its technical specifications and data from laboratory testing. Preclinical and early clinical data demonstrate the feasibility of this new method for noninvasive OAB treatment and possible implications for clinical practice.
Competing Interests: Jan Krhut is a consultant and investigator for STIMVIA™, Ostrava, Czech Republic. Lukas Peter and Martin Slovak are employees of STIMVIA™, Ostrava, Czech Republic. Michal Rejchrt is an investigator for STIMVIA™, Ostrava, Czech Republic. Barbora Skugarevska and Peter Zvara declare no conflicts of interest.
(Copyright © 2021 Jan Krhut et al.)
Databáze: MEDLINE
Externí odkaz: